UVB Phototherapy for Eczema and Skin Cancer: Why the Studies Do Not Give One Simple Answer
DOCTOR’S NOTES · ECZEMA EVIDENCE
When UVB phototherapy is proposed for eczema, “Does it cause skin cancer?” deserves a careful discussion. Recent studies do not support a universal zero-risk promise or a single percentage that applies to everyone. Treatment type, comparison group, skin-cancer subtype and cumulative exposure all affect what a result can mean.
An eczema-only cohort did not detect an increase
A 2023 retrospective cohort used data from 2001–2018 and included 6,205 people with atopic dermatitis. Comparing those receiving UVB with those not receiving it, the adjusted hazard ratio for skin cancer was 0.91, with a 95% confidence interval of 0.35–2.35. The study also found no association with the number of sessions.
The wide interval matters: it includes estimates below and above one. “No statistically detected increase” does not establish that UVB can never contribute to cancer. Treatment selection and other differences between people can also influence an observational comparison.
Finnish research asks a different comparison
A 2024 Finnish registry study followed 4,815 people treated with narrowband TL-01 UVB for psoriasis or atopic dermatitis, with mean follow-up of 8.4 years. It reported elevated skin-cancer incidence compared with population expectations. This was a mixed-diagnosis treated group, not a randomized comparison of eczema patients receiving versus not receiving treatment.
A September 2026 nested case-control analysis within that cohort examined individual session exposure. For basal-cell carcinoma, 38 cases were compared with 148 matched controls. The odds ratio per 20 sessions was 1.36, with a 95% confidence interval of 1.08–1.72. Only three basal-cell cases had atopic dermatitis; most had psoriasis. This estimate is therefore not an eczema-specific personal risk. The analysis lacked complete information on recreational sun exposure, skin phototype and some other possible confounders.
| Study question | Comparator | Important boundary |
|---|---|---|
| 2023 eczema cohort | UVB-treated versus untreated people with eczema | Retrospective; wide cancer-risk estimates |
| 2024 Finnish registry | Treated cohort versus expected population incidence | Mixed psoriasis/eczema population |
| 2026 exposure analysis | Cancer cases versus matched treated controls | Few cancers, especially eczema-specific cases |
Relative estimates are not extra cancers per 100 people
A hazard ratio, an odds ratio and a standardized incidence ratio are not interchangeable percentages. None of the numbers above alone tells a reader how many additional cancers their proposed course would cause. The studies also do not establish that a particular session threshold is universally safe below it or dangerous above it.
The 2026 analysis did not find the same exposure association for melanoma or squamous-cell carcinoma, but low case numbers limit reassurance about those outcomes. It would be equally misleading to quote only the reassuring study or only the concerning result while ignoring differences in design.
Turn uncertainty into a specific monitoring conversation
The AAAAI/ACAAI implementation guidance discusses prior skin cancer, photosensitivity, protective measures and monitoring for skin damage. Ask your dermatologist how personal history, other medicines and previous UV treatments influence the recommendation, how cumulative sessions are recorded and which skin changes require examination.
Our phototherapy appointment-planning article addresses time commitments, while sun protection versus phototherapy explains why ordinary sun exposure is a different issue. Do not replace prescribed treatment with tanning or extra outdoor UV, or stop a useful course without discussing the evidence and alternatives with the treating team.
Where everyday moisture care fits
Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration and moisture-barrier support. It does not treat, cure or prevent eczema and was not the intervention in the medical studies above. Follow the product label and your clinician’s instructions for how moisturizer fits alongside prescribed care.
When comparing alternatives, review their own evidence: the mycophenolate maintenance study and pediatric topical-steroid monitoring evidence answer different questions and do not supply a head-to-head ranking against phototherapy.
Sources and research
- 2023 atopic-dermatitis UVB cohort
- 2024 Finnish TL-01 registry study
- September 2026 nested case-control exposure analysis
- AAAAI/ACAAI guideline supplement: NB-UVB implementation
Prepared by the Dr. Arsy editorial team. Sources checked November 8, 2026. Educational content does not diagnose an individual or imply independent clinician review. The cited researchers and institutions do not endorse #003. Image is an AI-created product illustration, not a patient image or clinical result.